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Excessive bleeding at surgery is a feared complication in patientswith inherited platelet disorders. However, very few studies haveevaluated the frequency of surgical bleeding in these hemorrhagic
disorders. We performed a worldwide, multicentric, retrospective study
to assess the bleeding complications of surgery, the preventive and ther-
apeutic approaches adopted, and their efficacy in patients with inherited
platelet disorders: the Surgery in Platelet disorders And Therapeutic
Approach (SPATA) study. We rated  the outcome of 829 surgical proce-
dures carried out in 423 patients with well-defined forms of inherited
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platelet disorders: 238 inherited platelet function disorders and 185 inherited platelet number disorders.
Frequency of surgical bleeding was high in patients with inherited platelet disorders (19.7%), with a sig-
nificantly higher bleeding incidence in inherited platelet function disorders (24.8%) than in inherited
platelet number disorders (13.4%). The frequency of bleeding varied according to the type of inherited
platelet disorder, with biallelic Bernard Soulier syndrome having the highest occurrence (44.4%).
Frequency of bleeding was predicted by a pre-operative World Health Organization bleeding score of 2
or higher. Some types of surgery were associated with a higher bleeding incidence, like cardiovascular
and urological surgery. The use of pre-operative pro-hemostatic treatments was associated with a lower
bleeding frequency in patients with inherited platelet function disorders but not in inherited platelet
number disorders. Desmopressin, alone or with antifibrinolytic agents, was the preventive treatment
associated with the lowest bleedings. Platelet transfusions were used more frequently in patients at high-
er bleeding risk. Surgical bleeding risk in inherited platelet disorders is substantial, especially in inherited
platelet function disorders, and bleeding history, type of disorder, type of surgery and female sex are
associated with higher bleeding frequency. Prophylactic pre-operative pro-hemostatic treatments appear
to be required and are associated with a lower bleeding incidence.
Introduction 
Inherited platelet disorders (IPDs) are a heterogeneous
group of bleeding diseases of variable clinical severity
associated with a reduction of platelet number (inherited
platelet number disorders, IPNDs) and/or function (inher-
ited platelet function disorders, IPFDs). Spontaneous hem-
orrhages are mainly mucocutaneous and rarely serious,
while the hemorrhagic risk of trauma or surgery is not
well defined.1-3
Excessive bleeding at surgery is a feared complication of
IPDs and is empirically prevented or treated with platelet
transfusions, antifibrinolytic agents, desmopressin, or
recombinant activated factor VII (rFVIIa), although evi-
dence of the effectiveness of these measures is mostly
anecdotal.4-7
Two recent international collaborative studies have
assessed the delivery-associated bleeding risk and preg-
nancy outcome in a large series of patients with well-
defined forms of IPNDs or IPFDs.  These studies  have
shown that delivery-related maternal bleeding was more
frequent in IPDs than in healthy pregnant women, and
that the degree of thrombocytopenia and history of severe
bleeding were predictive of delivery-related hemorrhagic
risk.8,9 
Although guidelines for the management of bleeding
and of invasive procedures in patients with platelet disor-
ders and/or thrombocytopenia have been generated,10,11
they were not based on objective data on the incidence of
surgery-related bleeding, and thus were necessarily rather
generic.
Indeed, very few studies on surgery in IPDs have been
carried out. One retrospective study including 44 children
with mild bleeding disorders undergoing adeno-tonsillar
procedures, 27 of  whom had an unspecific platelet func-
tion disorder, concluded that prophylactic treatment with
desmopressin and tranexamic acid is effective in prevent-
ing perioperative bleeding.12 Another retrospective study
in 113 patients with congenital hemostatic disorders
undergoing general surgery or endoscopic procedures,
including 5 with platelet disorders, showed low morbidity
and mortality rates with desmopressin pre-treatment.13
With regard to well defined IPFDs, surgery outcome
was described mostly in case reports of patients with
Glanzmann thrombasthenia (GT), Bernard Soulier syn-
drome (BSS), or Hermansky-Pudlak syndrome (HPS).
Platelet transfusion for major surgery and antifibrinolytics
for minor invasive procedures were reported as effective
prophylactic measures for GT.14-16 Surgery-related bleed-
ing, when this occurred, was successfully treated with
rFVIIa17-19 or platelet transfusions.15 Platelet transfusions,
alone or in combination with antifibrinolytics20-22 or
desmopressin,22 prevented bleeding in BSS patients, while
platelet transfusions, alone23 or in combination with
rFVIIa,24 were used for HPS patients. However, no conclu-
sions on the rate of bleeding complications and its preven-
tion can be drawn from these studies.
Concerning the prevention and treatment of surgical
bleeding, the largest experience reported so far is the
recent evaluation of rFVIIa effectiveness and safety in 96
GT patients from an international observational registry,
showing that rFVIIa, administered alone or together with
platelet transfusions and/or antifibrinolytics, was effective
for both minor and major surgery.25 
With regard to IPNDs, platelet transfusions and, more
recently, eltrombopag have been reported to successfully
prevent bleeding without side-effects in a few MYH9-
related disease (MYH9-RD) patients.26-28 
The aim of the  Surgery in Platelet disorders And
Therapeutic Approach (SPATA) study was to evaluate the
bleeding complications associated with surgical proce-
dures, the therapeutic approaches adopted for the preven-
tion and treatment of hemorrhage, and their efficacy in a
large series of IPD patients diagnosed according to well-
defined, standardized criteria and undergoing a wide
range of invasive procedures. Here we report the results of
the analysis of the outcome of 829 surgical interventions
carried out in 423 patients with IPD.
Methods
Study population
This study was promoted by the Scientific Working Group
(SWG) on Thrombocytopenias and Platelet Function Disorders of
the European Hematology Association (EHA). The Institutional
Review Board of the co-ordinating center (CEAS Umbria, Italy)
approved the study, each center complied with local ethical rules,
and all patients or their legal representatives signed a written
informed consent. 
Participating investigators were asked to review their records
and extract data on surgery and invasive procedures carried out in
patients with IPDs over recent years [median 8; interquartile range
(IQR) 4-18 years] and to obtain additional data directly from the
surgeon who carried out the intervention or, if this was not possi-
ble, from the patient or his/her relatives. Only patients with a def-
inite diagnosis of IPD confirmed according to well-defined labora-
tory and/or molecular genetic criteria6,8-9 (Online Supplementary
Tables S1 and S2) were eligible for the study. IPDs were subdivided
into IPNDs, when low platelet count was the main phenotypic
characteristic (e.g. MYH9-RD), and IPFDs, when platelet dysfunc-
tion was the dominant phenotypic feature independently of
platelet count (e.g. autosomal dominant GT-variant) (Table 1).
Patients with acquired platelet disorders of any etiology were
excluded. All types of surgical procedures, including invasive diag-
nostic procedures (e.g. angiography, endoscopic and tissue biop-
sies) and dental extractions, were included. Caesarian sections
were excluded because these had been analyzed in a previous
study.8,9 
Surgical procedures were categorized post hoc as major surgery,
minor invasive procedures and dental procedures according to the
following criteria: a) major (any procedure in which a body cavity
was entered, a mesenchymal barrier was crossed, a facial plane
was opened, an organ was removed or normal anatomy was
altered); b) minor invasive (any operative procedure in which only
skin, mucous membranes or superficial connective tissue were
manipulated, gastroscopy, colonoscopy and similar); and c) dental
(i.e. extraction, abscess removal, apicectomy and similar).25 
Classification of bleeding
Bleeding history was assessed by the World Health
Organization (WHO) bleeding assessment scale29 and, when avail-
able, by the International Society of Thrombosis and Hemostasis
(ISTH) bleeding score scale.30 Severity of surgical bleeding was
defined according to three different criteria: 1) the Bleeding
Academic Research Consortium (BARC) classification, consider-
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Table 1. Diagnosis and features of study subjects.
IPFD N (% of total) Females (%) Age Platelet count (x109/L) WHO
(median-IQR) (median-IQR) (median-IQR)
Glanzmann thrombasthenia 89 (37.4) 53.9 33 (19-47) 245 (172-297) 3 (2-4)
Primary secretion defect 46 (19.3) 56.5 29 (14-46) 219 (160-272) 1.5 (1-3)
Bernard-Soulier syndrome (biallelic) 17 (7.1) 58.8 34 (21-49) 33 (20-39) 3 (2-3)
Delta granule deficiency 17 (7.1) 82.3 50 (37-59) 197 (141-232) 2 (1.75-3)
Hermansky–Pudlak syndrome 11 (4.6) 54.5 31 (24-50) 261 (228-321) 2 (1-2.5)
Gray platelet syndrome 10 (4.2) 30 31 (21-58) 65 (56-85) 2 (2-2)
Autosomal dominant GT-variant 10 (4.2) 90 45 (42-53) 85 (62-110) 1 (0.25-2)
Familial platelet disorder and predisposition 8 (3.4) 50 38 (24-51) 102 (93-139) 2 (1.75-2.25)
to acute myelogenous leukemia
Defects in 2-adrenergic receptor 6 (2.5) 33.3 19 (11-43) 178 (146-239) 1 (0.25-1.75)
Defects in collagen receptors 5 (2.1) 60 30 (23-59) 184 (126-256) 1 (0-2)
P2Y12 deficiency 5 (2.1) 40 36 (27-78) 190 (183-195) 2 (2-2)
Platelet-type von Willebrand disease 4 (1.7) 100 41 (31-52) 130 (113-168) 3 (2.75-3)
Defect of thromboxane A2 receptor 3 (1.3) 66.7 33 (29-52) 166 (129-169) 2 (2-2.5)
Scott syndrome 3 (1.3) 100 74 (58-75) 340 (-)* 1.5 (0.75-3)
CalDAG-related platelet disorder 2 (0.8) 50 54 (53-56) 267 (251-284) 3 (3-3)
Combined alpha-delta granule deficiency 2 (0.8) 50 52 (44-61) 85 (78-92) 0 (0-0)
TOTAL 238 (56.3% of 423) 58 36 (20-50) 191.5 (113-266) 2 (1-3)
IPND N (% of total) Females (%) Age Platelet count (x109/L) Median (IQR)
(median-IQR) (median-IQR)
MYH9-related disease 75 (40.5) 57.3 41 (31-56) 38 (22-50)1 1 (0-2)
ANKRD26-related thrombocytopenia 39 (21.1) 41 48 (38-67) 40 (29-54)2 1 (0-2)
Bernard-Soulier syndrome (monoallelic) 34 (18.4) 61.7 49 (42-60) 82 (61-105)3 1 (0-2)
ACTN1-related thrombocytopenia 17 (9.2) 76.4 43 (35-51) 93 (72-118)4 1 (0-2)
X-linked thrombocytopenia 7 (3.8) 0 29 (16-36) 34 (24-34) 1 (1-2)
Thrombocytopenia with absent radii 5 (2.7) 40 26 (17-30) 20 (16-31) 2 (0-2)
Paris-Trousseau thrombocytopenia 4 (2.2) 25 12 (7-16) 52 (18-115) 0.5 (0-1)
Congenital amegakaryocytic thrombocytopenia 2 (1.1) 50 9 (6-11) 61 (61-61) 1 (1-1)
FLNA-related thrombocytopenia 2 (1.1) 100 40 (33-47) 34 (29-38)5 1 (0.5-1.5)
TOTAL 185 (43.7% of 423) 53.5 43 (32-59) 50 (30-81) 1 (0-2)
Platelet count microscopic (x109/L): 155 (36-72); 250 (33-70); 391 (82-121.5); 4110 (93-129); 555.5 (47.25-63.75). *Only one count available. IPFD: inherited platelet function disorders;
IPND: inherited platelet number disorders; N: number; IQR: interquartile range; WHO: World Health Organization; GT: Glanzmann thrombasthenia.
ing as excessive any bleeding with a BARC 2 or more;31 2) a sub-
jective evaluation from the surgeon or, when not available, from
the patient;8,9 and 3) duration (from less than six hours to more
than three days), considered as excessive when more than six
hours. Procedures associated with excessive bleeding according to
any of the above three criteria were classified as any excessive
bleeding (AEB). 
When available, maximal drop of hemoglobin after surgery
(g/dL) was registered. 
Outcome of treatment of surgical bleeding was classified as suc-
cessfully controlled, not responsive or re-bleeding.  Not responsive
was an excessive bleeding episode that the treatment(s) applied
were not able to stop. Re-bleeding indicates a new episode of
bleeding occurring at a later time point after the procedure.
Statistical analysis
Data are reported as medians and 25th-75th percentiles (IQR)
when continuous and as counts and percentages when categorical.
Logistic regression was used to assess the association between
patients' or surgery characteristics with bleeding outcome. The χ2
test and Cochran-Armitage's Trend Test were used to compare
categorical data. R software (R Foundation for Statistical
Computing, Vienna, Austria; www.R-project.org) was used for all
analyses. Two-sided P<0.05 was considered statistically signifi-
cant.
Results 
Patients’ characteristics 
Four hundred and twenty-three patients (age 2-91 years;
median 40; IQR 23.7-54; 56% females), with 25 different
forms of IPDs (16 IPFDs and 9 IPNDs) enrolled by 49 cen-
ters across 17 countries underwent a total of 829 surgical
procedures. Two hundred and thirty-eight (56.3%; medi-
an age 36 years; 58% females), for a total of 455 proce-
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Table 2. Characteristics of surgical procedures according to diagnosis. 
IPFD N (% of total) Age at surgery Major Minor Dental 
(median-IQR) surgery (%) surgery (%) procedure (%)
Glanzmann thrombasthenia 182 (40) 31 (13-50) 43.9 15.4 40.7
Primary  secretion defect 76 (16.7) 26 (8-40) 69.7 10.5 19.7
Bernard-Soulier syndrome (biallelic) 36 (7.9) 30 (16-49) 52.8 19.4 27.8
Delta granule deficiency 36 (7.9) 50 (35-55) 72.2 13.9 13.9
Hermansky–Pudlak syndrome 22 (4.8) 16 (12-24) 63.6 18.2 18.2
Autosomal dominant GT-variant 22 (4.8) 23 (11-33) 63.6 0 36.4
Gray platelet syndrome 17 (3.7) 60 (22-69) 52.9 23.5 23.5
Defects in collagen receptors 16 (3.5) 10 (7-47) 56.2 12.5 31.2
Familial platelet disorder and 13 (2.8) 28 (20-48) 61.5 23.1 15.4
predisposition to acute myelogenous leukemia
Defects in 2-adrenergic receptor 9 (1.9) 36 (22-44) 44.4 22.2 33.3
P2Y12 deficiency 9 (1.9) 73 (72-76) 33.3 66.7 0
Defect of thromboxane A2 receptor 5 (1.1) 24 (21-30) 80 0 20
Platelet-type von Willebrand disease 5 (1.1) 34 (30-38) 40 40 20
Scott syndrome 3 (0.7) 74 (73-76) 66.7 33.3 0
CalDAG-related platelet disorder 2 (0.4) 30 (28-31) 50 0 50
Combined alpha-delta granule deficiency 2 (0.4) - 0 50 50
TOTAL 455 (54.9% of 829) 31 (15-52) 54.5 16 29.5
IPND N (% of total) Age at surgery Major Minor Dental 
(median-IQR) surgery (%) surgery (%) procedure (%)
MYH9-related disease 148 (39.6) 28 (12-47) 64.9 6.7 28.4
ANKRD26-related thrombocytopenia 89 (23.8) 35 (19-50) 70.8 2.2 26.9
Bernard-Soulier syndrome (monoallelic) 74 (19.8) 34 (20-51) 67.6 12.2 20.3
ACTN1-related thrombocytopenia 39 (10.4) 30 (9-44) 66.7 10.3 23.1
X-linked thrombocytopenia 9 (2.4) 20 (17-26) 44.4 0 55.5
Thrombocytopenia with absent radii 6 (1.6) 16 (10-27) 50 33.3 16.7
Paris-Trousseau thrombocytopenia 5 (1.3) 1 (1-4) 80 0 20
Congenital amegakaryocytic thrombocytopenia 2 (0.5) 8 (6-11) 50 50 0
FLNA-related thrombocytopenia 2 (0.5) 23 (17-28) 0 0 100
TOTAL 374 (45.1% of 829) 31 (14-47) 66 7.5 26.5
IPD: inherited platelet disorders; IPFD: inherited platelet function disorders; IPND: inherited platelet number disorders; N: number; AEB: any excessive bleeding; IPFD: inherited
platelet function disorders; IPND: inherited platelet number disorders; N: number; IQR: interquartile range; GT: Glanzmann thrombasthenia.
dures, had  an IPFD and 185 (43.7%; median age 43 years;
53.5% females), for a total of 374 procedures, an IPND.
Diagnosis and baseline characteristics are reported in
Table 1. In order of frequency, IPFDs were GT, primary
secretion defect, biallelic BSS (bBSS), δ granule deficiency,
HPS, Gray platelet syndrome (GPS) and autosomal domi-
nant GT-variant;  IPNDs were, in order,  MYH9-related
disorder, ANKRD26-related thrombocytopenia, monoal-
lelic BSS (mBSS), ACTN1-related thrombocytopenia.
Bleeding history was on average mild (WHO grade medi-
an 2, IQR 1-3), but 25% of patients had a WHO grade 3
(79.8% of which were IPFD) and 3.3% a WHO grade 4
(64.3% of which were IPFD) (Online Supplementary Figure
S1). Thrombocytopenia in IPNDs was on average mild
(median 68x109/L; IQR 30-81x109/L) but 50% of patients
had a platelet count less than 50x109/L and 25% less than
30x109/L. The ISTH bleeding assessment tools (BAT)
bleeding score was available for 143 patients (33.5%),
with a median score of 3 in the overall IPD population
(IQR 1-7), 6 (IQR 2-11.25) for IPFD (n=89), and 1 (IQR 0-
1) for IPND (n=54).
Type of surgery and prophylactic treatments
Procedures were: 59.7% major surgeries, 28.1% dental,
and 12.2% minor invasive. Among major surgeries, the
most frequent procedures were abdominal (15.2%),
otorhinolaryngological (12.8%), gynecological (6.8%), and
orthopedic (6.8%). Median age at surgery was 31 years for
both IPFDs (IQR 15-52) and IPNDs (IQR 14-47.5). In
IPND, median platelet count at surgery was 56x109/L (IQR
40-93). Table 2 summarizes the characteristics of surgical
procedures according to IPD diagnosis. 
An anti-hemorrhagic prophylactic pre-operative treat-
ment was administered in 57.2% of the procedures, in
particular in 80.6% of procedures in patients with IPFDs
and in 20.6% of procedures in IPNDs. Frequency of use of
pre-operative prophylaxis was independent of the type of
surgery; in fact, for IPFDs, 77.4% of major surgeries,
87.7% of minor invasive procedures, and 82.8% of dental
procedures were treated; for IPNDs these were 28.7%,
35.7%, and 26.3%, respectively. In contrast, administra-
tion of a prophylactic treatment was positively correlated
with pre-operative WHO bleeding score (Cochran-
Armitage trend test P<0.0001) (Figure 1A). Moreover,
among IPNDs, the use of prophylactic pro-hemostatic
treatment was negatively associated with platelet count
quartiles (Cochran-Armitage trend test P<0.0001) (Figure
1B). 
Most frequently used prophylactic treatments were
platelet transfusions (26.8% for IPFDs and 20.6% for
IPNDs), followed by antifibrinolytic agents (11.2% for
IPFDs and 4% for IPNDs), a combination of both (12.3%
for IPFDs and 1.3% for IPNDs), desmopressin (8.1% for
IPFDs and 1.1% IPNDs), desmopressin with antifibri-
nolytic agents (7.9% for IPFDs and 0% in IPND), and
rFVIIa (5.9% for IPFDs and 0% for IPNDs) (Table 3). The
use of prophylactic treatments according to diagnosis is
reported in Table 4.
Platelet transfusions consisted of fresh platelets from
random donors in 97.1% of cases, 34.2% of which were
HLA-matched, and of cryopreserved platelets in 2.9% of
the procedures. In IPNDs, platelet transfusions were used
more frequently in patients with platelet counts of
50x109/L or lower (OR 2.73, 95%CI: 1.63-4.61; P=0.0001)
S. Orsini et al.
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Table 3. Prophylactic treatments according to disease category and type of surgery. 
IPD IPFD IPND Major surgery Minor surgery Dental procedures
Prophylaxis N (%) % AEB N (%) % AEB N (%) % AEB N (%) % AEB N (%) % AEB N (%) % AEB
None 355 (42.8) 19.7 88 (19.3) 40.9 267 (71.4) 12.7 232 (46.9) 20.8 27 (26.7) 21.4 96 (41.2) 16.7
Any 474 (57.2) 19.6 367 (80.7) 20.9 107 (28.6) 14.9 263 (53.1) 22.8 74 (73.3) 24.3 137 (58.8) 10.9
PT 199 (24) 26.3 122 (26.8) 31.4 77 (20.5) 18.2 137 (27.7) 29.2 33 (32.7) 33.3 29 (12.4) 3.6
AA 66 (8) 15.1 51 (11.2) 17.6 15 (4) 6.7 15 (3.0) 6.7 12 (11.9) 33.3 39 (16.7) 12.8
PT+AA 61 (7.4) 16.1 56 (12.3) 17.5 5 (1.3) 0 30 (6.1) 20.0 8 (7.9) 25.0 23 (9.9) 8.3
DDAVP 41 (4.9) 7.3 37 (8.1) 8.1 4 (1.1) 0 17 (3.4) 17.6 8 (7.9) 0 16 (6.9) 0
DDAVP+AA 36 (4.3) 8.3 36 (7.9) 8.3 31 (6.3) 3.2 5 (2.1) 40.0
FVIIa 27 (3.3) 18.5 27 (5.9) 18.5 7 (1.4) 14.3 9 (8.9) 11.1 11 (4.7) 27.3
Other 17 (2.1) 35.3 11 (2.4) 45.4 6 (1.6) 16.7 12 (2.4) 33.3 2 (2.0) 0 3 (1.3) 66.7
PT+AA+DDAVP 8 (1) 0 8 (1.7) 0 6 (1.2) 0 2 (0.9) 0
FVIIa+AA 7 (0.8) 14.3 7 (1.5) 14.3 1 (0.2) 100 1 (1.0) 0 5 (2.1) 0
PT+ Other 4 (0.5) 50.0 4 (0.9) 50.0 3 (0.6) 66.7 1 (0.4) 0
AA+Other 3 (0.4) 33.3 3 (0.7) 33.3 1 (0.2) 100
PT+DDAVP 2 (0.2) 0 2 (0.4) 2 (0.4) 0
FVIIa+AA+ Other 1 (0.1) 0 1 (0.2) 1 (1.0) 0
PT+DDAVP+ Other 1 (0.1) 0 1 (0.2) 1 (0.4) 0
PT+FVIIa 1 (0.1) 0 1 (0.2) 1 (0.2) 0
TOTAL 829 19.66 455 24.84 374 13.37 495 21.86 101 23.53 233 13.30
IPD: inherited platelet disorders; IPFD: inherited platelet function disorders; IPND: inherited platelet number disorders; N: number; AEB: any excessive bleeding; PT: platelet trans-
fusion; AA: antifibrinolytic agents; DDAVP: desmopressin; FVIIa: activated factor VII; Other: cryoprecipitate, fibrin-glue, fibrinogen, fresh frozen plasma, intravenous immunoglob-
ulin, local hemostatic agent, suture, local tranexamic acid (for IPFD); Eltrombopag, fresh frozen plasma, intravenous immunoglobulin, local hemostatic agent, prophylactic sur-
gical hemostasis (for IPND). 
and in those undergoing major surgery (OR 1.94, 95% CIs
1.10-3.42; P=0.02), while in IPFDs they were used more
frequently in patients with a WHO of 2 or higher (OR
2.22, 95%CI: 1.37-3.59; P=0.001) and in those undergoing
major surgery (OR 1.45, 95%CI: 1-2.12; P=0.051). 
Bleeding outcome 
Excessive bleeding after surgery occurred in 163 of the
surgical procedures in the overall IPD population (19.7%),
when assessed by any of the pre-defined criteria (i.e. AEB),
i.e. 1 episode of bleeding every 5 procedures. Excessive
bleeding occurred in 15.3% of the procedures when
scored as higher than 2 by the BARC classification, in
15.3% when assessed by subjective evaluation, and in
10.5% when defined by a duration of more than six hours
(Online Supplementary Figure S2).
When the two populations were analyzed separately,
AEB was reported almost twice as frequently in IPFDs,
who suffered AEB in 24.8% of the procedures, than in
IPNDs, for whom AEB was reported in 13.4% of the pro-
cedures. The drop in hemoglobin  was 1.29 g/dL (95%CI:
0.89-1.68) for IPFD (n=83), and 0.53 g/dL (95%CI: 0.17-
0.89) for IPND (n=30) (P=0.005).
Among IPFDs, AEB was reported more frequently in
bBSS (44.4%), familial platelet disorder / acute myeloid
leukemia (FPD/AML) (30.7%), GT (29.1%), HPS (27.3%),
GPS (23.5%), and autosomal-dominant GT-variant
(22.7%) than in the overall IPFD population. bBSS and GT
patients received pre-operative prophylactic treatment in
97.2% and 90.6% of procedures, respectively, emphasiz-
ing the perceived high surgical bleeding risk associated
with these disorders. 
Among IPNDs, AEB was reported more frequently in
MYH9-RD patients (15.5%) than in the overall IPND pop-
ulation. The distribution of bleeding outcomes in the indi-
vidual IPDs is shown in Online Supplementary Table S3. 
Frequency of excessive bleeding in the overall IPD pop-
ulation was 21.8% after major surgery, 23.8% after minor
invasive procedures, and 13.3% after dental procedures,
(for IPFDs, 28.6%, 28.8%, and 15.7%, respectively, and
for IPNDs, 15%, 10.7%, and 10.1%). 
In the overall IPD population, AEB was reported more
frequently after cardiovascular surgery (47.1%), followed
by urological (34.2%), gynecological (26.8%), otorhino-
laryngological (24.5%), plastic (21.4%), eye (20%), and
abdominal (19.8%) surgery. Incidence of bleeding in the
different IPD populations according to the type of surgery
is shown in Table 5.  
Any excessive bleeding, occurring during the first proce-
dure was a risk factor for the recurrence of bleeding during
a second (IPFD: OR 6.7, 95%CI: 2.3-18.9, P=0.0004; IPND:
OR 3.82, 95%CI: 1.09-13.4, P=0.0357) or third  (IPFD: OR
10, 95%CI: 1.1-90.6, P=0.04; IPND: OR 27, 95%CI: 2.2-
324.9, P=0.0094) procedure.
Characteristics associated with post-surgical bleeding
A significant association was found between the fre-
quency of AEB and clinical bleeding history assessed by
the WHO bleeding score, both in the overall IPD popula-
tion (WHO 1=OR 2.6, 95%CI: 1.0-6.9; WHO 2=OR 5.7,
95%CI: 2.4-13.6; WHO 3=OR 11.2, 95%CI: 4.7-26.7;
WHO 4=OR 17.5, 95%CI: 5.6-54.7) and in the two popu-
lations analyzed separately (Table 6 and Figure 2A). The
association between the WHO bleeding score and AEB
was also maintained when procedures were subdivided
into major, minor invasive and dental (Figure 2B). 
Among IPFDs, a higher frequency of post-surgical bleed-
ing was observed in females (Table 6). To exclude the pos-
sibility that this might be due to the relatively high bleed-
ing rate associated with gynecological procedures, we re-
evaluated the association between sex and AEB after
excluding gynecological procedures. Results confirmed
that female sex is a risk factor for post-surgical bleeding in
IPFDs [OR 1.70 (1.05-2.77); P=0.03]. 
A higher frequency of post-surgical bleeding was
observed in some disorders, like bBSS, GT and HPS
(Online Supplementary Table S4). 
Finally, in IPND, a platelet count below the median
(68x109/L) and an age over 70 were associated with a sig-
nificantly higher frequency of post-surgical bleeding
(Table 4). 
Efficacy of prophylactic treatments
The use of a prophylactic anti-hemorrhagic preparation
was associated with a markedly reduced frequency of sur-
gical bleeding in IPFDs (OR 0.38; 95%CI: 0.23-0.63) (Table
6). Indeed, AEB was reported more frequently in patients
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Figure 1. Frequency of prophylactic treatments according to World Health
Organization (WHO) bleeding score and platelet count. (A) Use of prophylactic
pre-operative treatments according to pre-operative WHO bleeding score in the
overall inherited platelet disorder (IPD) population, in inherited platelet function
disorder (IPFDs) and inherited platelet number disorder (IPNDs). (B) Use of pro-
phylactic pre-operative treatments according to pre-operative platelet count
quartiles (x109/L) (microscopic) in IPNDs.   
A
B
not receiving a prophylactic treatment than in those
receiving it (40.9% vs. 21%; P<0.01). 
Post-surgical bleeding was lowest in desmopressin-treat-
ed patients (AEB in 8.1% of procedures, OR 0.13; 95%CI:
0.04-0.45, as compared with no treatment), followed by
desmopressin and antifibrinolytic agents (8.3%, OR 0.13;
95%CI: 0.04-0.46), antifibrinolytic agents alone (17.6%,
OR 0.31; 95%CI: 0.13-0.71), antifibrinolytic agents and
platelet transfusions (17.8%, OR 0.31; 95%CI: 0.14-0.70),
and rFVIIa (18.5%, OR 0.33; 95%CI: 0.11-0.95). Platelet
transfusions alone, the majority of which were, however,
given to patients with WHO grade 3 or higher (86.8%)
and/or undergoing major surgery (68.4%), were not associ-
ated with a lower frequency of AEB (31.1%).
Information about platelet transfusion modalities was
obtained for 123 out of 276 procedures in which these
were used. The median platelet transfusion dose was 4
units (2-8), significantly higher in IPFDs (5, range 4-8) than
in IPNDs (2.5, range 1-4) (P=0.0007). The median time of
administration before the procedure was 1 hour (ranging
from a few minutes to 3 days). Among GT patients, the
dose of platelet transfusions was recorded in 58 proce-
dures: AEB was reported in 12 of them (20.7%) and
occurred more frequently when the amount of platelets
transfused was less than 6 units (9 of 12, 75%) than when
it was more than 6 units (3 of 12, 25%) (P=0.04 by χ2 test).
Moreover, information about platelet refractoriness and/or
antiplatelet antibody positivity was obtained for 42 GT
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Table 4. Prophylactic treatments according to diagnosis. 
IPFD Prophylatics/total PT AA PT+AA DDAVP DDAVP+AA FVIIa Other
(% of treated) (%) (%) (%) (%) (%) (%) (%)
Glanzmann thrombasthenia 155/182 (90.7) 54 (34.8) 30 (19.3) 35 (22.6) 6 (3.9) (0) 24 (15.5) 6 (3.9)
Primary secretion defect 62/76 (85.5) 9 (14.5) 9 (14.5) 6 (9.7) 15 (24.2) 23 (37.1) (0) (0)
Bernard-Soulier syndrome (biallelic) 34/36 (97.2) 26 (76.5) 1 (2.9) 3 (8.8) 1 (2.9) 2 (5.9) (0) 1 (2.9)
Delta granule deficiency 25/36 (83.3) 2 (8) 3 (12) 6 (24) 5 (20) 9 (36) (0) (0)
Hermansky–Pudlak syndrome 11/22 (50) 4 (36.4) 1 (9.1) 1 (9.1) 4 (36.4) (0) 1 (9.1) (0)
Autosomal dominant GT-variant 6/22 (36.4) 2 (33.3) 2 (33.3) 2 (33.3) (0) (0) (0) (0)
Gray platelet syndrome 12/17 (70.6) 8 (66.7) 2 (16.7) (0) (0) 1 (8.3) (0) 1 (8.3)
Defects in collagen receptors 6/16 (37.5) (0) 1 (16.7) (0) 2 (33.3) (0) 1 (16.7) 2 (33.3)
Familial platelet disorder and predisposition 6/13 (61.5) 4 (66.7) 1 (16.7) 1 (16.7) (0) (0) (0) (0)
to acute myelogenous leukemia 
Defects in 2-adrenergic receptor 7/9 (77.8) 3 (42.9) 1 (14.3) 1 (14.3) 2 (28.6) (0) (0) (0)
P2Y12 deficiency 7/9 (77.8) 5 (71.4) (0) (0) 1 (14.3) (0) (0) 1 (14.3)
Defect of thromboxane A2 receptor 3/5 (60) (0) (0) 1 (33.3) 1 (33.3) 1 (33.3) (0) (0)
Platelet-type von Willebrand disease 1/5 (40) 1 (100) (0) (0) (0) (0) (0) (0)
Scott syndrome 3/3 (100) 2 (66.7) (0) (0) (0) (0) 1 (33.3) (0)
CalDAG-related platelet disorder 2/2 (100) 2 (100) (0) (0) (0) (0) (0) (0)
Combined alpha-delta granule deficiency 0/2 (0)
TOTAL 455 (80.7) 122 51 56 37 36 27 11
IPND Prophylaxed/total PT AA PT+AA DDAVP DDAVP+AA FVIIa Other
(% of treated) (%) (%) (%) (%) (%) (%) (%)
MYH9-related disease 53/148 (35.8) 42 (79.2) 8 (15.1) 3 (5.6)
ANKRD26-related thrombocytopenia 24/89 (27) 18 (75) 1 (0.4) 1 (0.4) 3 (12.5) 1 (0.4)
Bernard-Soulier syndrome (monoallelic) 13/74 (17.6) 7 (53.8) 5 (38.5) 1 (7.7)
ACTN1-related thrombocytopenia 0/39 (0)
X-linked thrombocytopenia 6/9 (66.7) 2 (33.3) 3 (50) 1 (16.7)
Thrombocytopenia with absent radii 4/6 (66.7) 3 (75) 1 (25)
Paris-Trousseau thrombocytopenia 5/5 (100) 3 (60) 1 (20) 1 (20)
Congenital amegakaryocytic thrombocytopenia 2/2 (100) 2 (100)
FLNA-related thrombocytopenia 0/2 (0)
TOTAL 374 (28.6) 77 15 5 4 6
IPFD: inherited platelet function disorder; PT: platelet transfusion; AA: antifibrinolytic agents; DDAVP: desmopressin; FVIIa: activated factor VII; IPND: inherited platelet number
disorder; prophylactic treatments with sample size <10 not shown. Other: cryoprecipitate; fibrin-glue, fibrinogen, fresh frozen plasma, intravenous immunoglobulin, local hemo-
static agent, suture, local tranexamic acid (for IPFD), Eltrombopag, fresh frozen plasma, intravenous immunoglobulin, local hemostatic agent, prophylactic surgical hemostasis
(for IPND).
patients undergoing 143 invasive procedures in which
platelet transfusions were given as prophylaxis. The
bleeding rate (AEB) was 23.3% in those without and
37.5% in those with a history of platelet refractoriness or
anti-platelet antibodies (P=not significant, ns). 
In contrast to IPFDs, prophylactic treatments did not
seem to modify surgery-related bleeding frequency in
IPNDs, since, indeed, AEB was reported in 12.7% of the
procedures carried out without preparation (34 of 267) and
in 14.9% of the procedures carried out with pre-operative
prophylaxis (16 of 107). But in fact, antifibrinolytic agents
were associated with a lower post-surgical bleeding fre-
quency in IPNDs (AEB in 6.7% of procedures), while other
treatments were not. In particular, platelet transfusions
were not associated with lower post-surgical bleeding,
although it must be considered that they were mainly
given to patients undergoing major surgery. 
Treatment of bleeding and outcome 
Surgical procedures followed by AEB received an emer-
gency treatment in 86.7% of the cases (98 of 113) for
IPFDs (platelet transfusions 60.2%, antifibrinolytic agents
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Table 5. Incidence of bleeding in the different inherited platelet disorder populations according to the type of surgery.
                                                                      IPD                                    IPFD                                      IPND                         IPFD vs. IPND 2
Procedure                                                 N (% AEB)                           N (% AEB)                               N (% AEB)                                  P
DENTAL PROCEDURES                                    233 (13.3)                                  134 (15.7)                                       99 (10.1)                                            
MINOR SURGERY:                                                                                                                                                                                                                       
Cyst/abscess drainage                                          5 (60)                                       3 (66.7)                                           2 (50)                                            ns
Central catheter placement                             11 (36.4)                                     9 (44.4)                                            2 (0)                                             ns
Hemorrhoidectomy                                               8 (25)                                       3 (33.3)                                           5 (20)                                            ns
Invasive procedure                                              25 (20)                                     15 (26.7)                                         10 (10)                                           ns
Colonoscopy                                                          25 (20)                                     21 (23.8)                                           4 (0)                                             ns
Gastroscopy                                                         11 (18.2)                                     10 (20)                                             1 (0)                                             ns
Biopsy                                                                    17 (17.6)                                    13 (23.1)                                           4 (0)                                             ns
TOTAL minor surgery                                        102 (23.5)                                   74 (28.4)                                        28 (10.7)                                         ns 
MAJOR SURGERY:                                                                                                                                                                                                                       
Thoracic surgery                                                    2 (50)                                         2 (50)                                                                                                    ns 
Cardiovascular surgery                                     17 (47.1)                                     9 (77.8)                                          8 (12.5)                                         0.02
Urological surgery                                              38 (34.2)                                    24 (37.5)                                        14 (28.6)                                         ns 
Neurological surgery                                          7 (28.6)                                       5 (20)                                             2 (50)                                            ns 
Gynecological surgery                                       56 (26.8)                                    31 (35.5)                                         25 (16)                                           ns 
Otorinolaringological surgery                        106 (24.5)                                   49 (24.5)                                        57 (24.6)                                         ns 
Plastic surgery                                                     14 (21.4)                                      4 (25)                                            10 (20)                                           ns 
Eye surgery                                                            25 (20)                                     12 (41.7)                                          13 (0)                                           0.03
Abdominal surgery                                            126 (19.8)                                   52 (30.8)                                        74 (12.2)                                        0.01
Orthopedic surgery                                           56 (12.5)                                    30 (16.7)                                         26 (7.7)                                          ns 
Breast surgery                                                      13 (7.7)                                      7 (14.3)                                            6 (0)                                             ns 
Dermatologic surgery                                         34 (5.9)                                      22 (9.1)                                           12 (0)                                            ns 
TOTAL major surgery                                        494 (21.9)                                  247 (28.7)                                       247 (15)                                      0.0003
TOTAL                                                                   829 (19.7)                                  455 (24.8)                                      374 (13.4)                                     0.0001
IPD: inherited platelet disorder; IPFD: inherited platelet function; IPND: inherited platelet number disorder; vs.: versus; N: number: AEB: any excessive bleeding; ns: not significant. 
Table 6. Univariate and multivariate logistic analyses of factors associated with surgical bleeding. 
IPFD (n=455) IPND (n=374)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Female 1.8 (1.1-2.9) 1.28 (2.13-0.76) - -
WHO bleeding score
Grade 0 1.00 1.00 1.00 1.00
Grade 1 0.91 (0.17-4.97) 1.29 (0.23-7.35) 4.27 (1.34-13.57)
Grade 2 3.87 (0.87-17.17) 4.96 (1.08-22.82) 5.16 (1.69-15.79)
Grade 3 6.62 (1.52-28.89) 8.47 (1.83-39.13) 10.9 (3.28-36.25)
Grade 4 10 (1.8-55.53) 19.23 (3.23-114.55) 20.44 (3.38-123.53)
Platelet count <68x109/L - - 2.04 (1.01-4.12)
Age ≥ 70 years 1.84 (1.009-3.37)
Prophylaxis 0.38 (0.23-0.63) 0.24 (0.14-0.43) - -
IPFD: inherited platelet function; IPND: inherited platelet number disorder; OR: Odds Ratio; CI: Confidence Interval; WHO: World Health Organization.
17.3%, other 11.2%, FVIIa 6.1%), and in 62% for IPNDs
(31 of 50) (other 41.9%, platelet transfusions 38.7%, and
antifibrinolytic agents 19.3%). Treatment of bleeding
according to disorder and type of surgery is reported in
Online Supplementary Table S4. Successful control was
obtained in 73.4% of IPFDs and in 58% of IPNDs.
The most effective treatments were antifibrinolytic
agents (88.2% of bleedings controlled; 15 of 17), platelet
transfusions (83% of bleedings controlled; 49 of 59), and
other treatments (fresh frozen plasma, stitches, ice, com-
pression and dressing; 100% of bleedings controlled, 10 of
10) for IPFDs, while for IPNDs, these were platelet trans-
fusions (100% of bleedings controlled, 12 of 12), followed
by other treatments (surgical hemostasis, packing, com-
pression, stitches; 92.3% of bleedings controlled, 12 of 13),
and antifibrinolytic agents (83.3% of bleedings controlled,
5 of 6). 
In 21 procedures carried out in 18 patients (12.9% of the
procedures with AEB) outcome of bleeding was unfavor-
able (19 re-bleeding, 2 not responding to treatment). Of
these, 80.9% occurred in IPFD (12 GT, 1 bBSS, 1 primary
secretion defect, 1 CalDAG-related platelet disorder, 1
GPS, 1 defect of TP receptor) and 19.1% in IPNDs (3
MYH9-RD, 1 ANKRD-26 related thrombocytopenia).
Among these patients, 1 patient  had a WHO grade 0, 9
patients a WHO grade 2, 10 patients a WHO grade  3, and
1 patient a WHO grade 4. The majority of these proce-
dures (n=15) were major surgeries, but 3 were
colonoscopy with polypectomy, 2 dental procedures, and
one an enteroscopy for an angiodysplasia;  in 76.2% of
them, prophylaxis had been administered before surgery.
Re-bleeding was treated mainly with platelet transfusions
and/or antifibrinolytic agents and resolved in all but 2
cases, a 32-year old man with GT undergoing partial lung
resection for recurrent severe hemoptysis and a 51-year
old man with MYH9-RD undergoing endovascular treat-
ment of an intracranial aneurysm for whom the outcome
was death.
Discussion
Although IPDs are conventionally considered to be rare,
at least 14,000 patients  each year undergo investigations
worldwide for a suspected IPD and over 5600 new diag-
noses are made.2 Therefore, cases in which a surgeon may
have to deal with a patient with an IPD are not unexpect-
ed events, and knowledge of the bleeding risks associated
with the distinct invasive procedures and the different
platelet disorders may be of great help in guiding surgical
management. 
Our study of 829 surgical procedures in 423 patients rep-
resents the largest experience reported so far on surgery in
patients with IPDs.
The study shows that the frequency of excessive bleed-
ing associated with surgery in patients with IPD is sub-
stantial, varying from 9.9% to 19.7%, depending on the
definition used. In particular, it is striking that bleeding fre-
quency is almost double in platelet function disorders
compared with thrombocytopenias, ranging from 15.4%
to 24.8%, depending on the definition used. The frequen-
cy of AEB appeared to be especially high for some disor-
ders, including bBSS, FPD/AML, GT and HPS, with up to
44.4% of the procedures resulting in  excessive bleeding. 
Some of the findings of the present study provide novel
and relevant clinical information on the bleeding risk asso-
ciated with IPFDs. In fact, while a high bleeding risk of GT
and bBSS is generally considered acceptable, the high fre-
quency of surgery-associated bleeding in HPS, FPD/AML,
GPS and autosomal-dominant GT-variants was unexpect-
ed because they are commonly considered to be  non-
severe. However, it can not be excluded that AEB in these
patients was due to the infrequent use of a pre-operative
prophylactic treatment, probably consequent to the
assessment of these disorders as 'mild'. Other IPFDs, too,
like platelet type-von Willebrand disease (PT-VWD),
TXA2 receptor defect and CalDAG-related platelet disor-
der, suffered frequent post-surgical bleedings, although
this observation can only be considered anecdotal given
the low number of patients enrolled. On the other hand,
other IPFDs showed a low bleeding risk, like collagen
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Figure 2. Post-surgical bleeding in inherited platelet disorders (IPD). (A)
Incidence of any excessive bleeding (AEB) in the overall IPD population, in inher-
ited platelet function disorders (IPFDs) and in inherited platelet number disorder
(IPNDs) according to pre-surgical World Health Organization (WHO) bleeding
score. (B) Incidence of AEB in the different procedures according to pre-surgical
WHO bleeding score.
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receptor defects, δ-granule deficiency, and primary secre-
tion defects. Given that pre-operative prophylaxis was
administered in only 37.5% of the procedures in patients
with collagen receptor defects, these seem, indeed, to be
mild disorders.
Inherited platelet number disorders  were associated
with infrequent surgical bleeding, ranging from 5.4% to
13.3%, depending on the definition, with no significant
differences observed among the different disorders. 
Given that 21% of the enrolled patients were GT, and
that a prophylactic treatment was administered in 90.7%
of the procedures carried out in this patient subgroup, the
impact of this on the overall analysis was evaluated by
excluding the procedures carried out in GT. AEB in the
remaining IPFD population was 21.9%, not significantly
different from the 24.8% observed in the total IPFD pop-
ulation (P=ns, χ2).
The same procedure was applied to IPNDs by excluding
MYH9-RD; AEB in the remaining IPND population was
11.9%, with no difference  from the 13.4% of the total
IPND population (P=ns, χ2 test). 
In IPNDs, 68x109/L platelets was the threshold below
which bleeding rate increased significantly; a value very
similar to that previously identified as predictive of bleed-
ing at childbirth.8
In the overall IPD population, bleeding history was
highly predictive of surgical bleeding. In fact, a WHO
grade of  2 or higher was associated with a more than 4-
fold increase in bleeding rate. Moreover, bleeding occur-
ring after the first surgical procedure strongly predicted
the rate of bleeding in subsequent procedures.
Of note, bleeding tendency was higher in IPFDs than in
IPNDs, with 79.8% of patients with a WHO grade 3 and
64.3% with a WHO grade 4 being IPFD.8,9,32 Similarly, in
the subgroup of patients for whom the ISTH BAT bleed-
ing score was available, this was highly predictive of post-
surgical bleeding, with an ISTH BAT of 6 or more associ-
ated with a strongly increased bleeding risk.
Some types of surgery were associated with higher
bleeding risk, like cardiovascular or urological surgery. On
the other hand, also minor invasive procedures were asso-
ciated with bleeding, suggesting that prophylactic meas-
ures also need to be applied  to procedures such as gas-
troscopy with biopsy.
Administration of an anti-hemorrhagic prophylactic
treatment was associated with a reduced bleeding fre-
quency in the IPFD population but not in IPND. This
seems to be reflected in the current practice, likely based
on expert consultation, given that, in our study,  the vast
majority of patients with IPFDs   received prophylaxis
(80.6%), while patients with IPND  only occasionally
received prophylaxis (20.6%). 
The apparent lower efficacy of pre-operative prophylax-
is in IPND patients may derive from the lower absolute
bleeding risk in this subpopulation, with consequent
lower statistical power to detect reduced bleeding in  sub-
jects receiving prophylaxis, and/or by the use of milder
prophylactic measures (lower dosage, shorter duration,
etc.) due to the perception of a lower bleeding risk. On the
other hand, the choice of the preventive measures did not
appear to be always appropriate, since platelet transfu-
sions, the most frequently used prophylactic treatment,
was shown to be poorly effective, with bleeding occurring
in 30.1% of the procedures in which they were used.
These data are in agreement with previous findings in
pregnancy.8,9 However, it should be considered that
platelet transfusions were most frequently used in patients
with severe bleeding disorders and/or undergoing major
surgery, and that the mode of administration of platelet
transfusions was rather heterogeneous, and possibly
sometimes incongruous. These observations suggest that
the way platelet transfusions are employed (amount, type,
timing) is often inappropriate.33,34
The most effective prophylactic treatment was desmo-
pressin, alone or in combination with antifibrinolytic
agents, while antifibrinolytic agents used alone were less
effective. In particular, desmopressin was used as prophy-
laxis in 88 procedures (10.3% minor invasive, 26.1% den-
tal, and 63.6% major procedures), only 6 of which were
followed by AEB (7%), 4  (66.7%) after major surgeries,
and 2 (33.3%) after dental procedures. Interestingly,
31.9% (28 of 88) of patients in whom desmopressin was
used had a severe bleeding history (WHO grade 3) and
only 3 of them suffered AEB,  supporting the efficacy of
this pro-hemostatic treatment for IPFDs, even for the
more severe conditions.
Activated recombinant factor VII, an approved treat-
ment for GT, was seen  to be a good prophylactic meas-
ure, in line with previous results.25 In our cohort of
patients, rFVIIa alone was used as a prophylaxis in 36
patients, 32 of whom were GT;  55%  of these patients
had a WHO grade 1 or 2, 33% had a WHO grade 3 and
2.7% had a WHO grade 4. rFVIIa was used in  cases of
minor invasive procedures (27.8%),  dental procedures
(47.2%), and  major procedures (25%). These data suggest
that rFVIIa is efficacious also for severe cases and when
used alone. 
Although the current study does not provide any data
on the safety of the prophylactic measures, previous expe-
rience suggests that they are generally well tolerated. Mild
adverse effects of desmopressin may include headache,
nausea and hypotension, although sometimes more seri-
ous side effects, such as hyponatremia and renal dysfunc-
tion, may occur. After antifybrinolytic agents allergic or
anaphylactic reactions and sometimes headache may
occur. Finally, pro-hemostatic agents, and in particular
recombinant FVIIa, may predispose to thrombotic compli-
cations; however, the latter are relatively rare and depend
on the thrombotic risk profile of the patient and the pro-
cedure.5,35 
Finally, treatment of surgical bleeding was successful in
most IPFD cases (73.4%), and in a slightly lower number
of IPND cases (58%). 
Our study has several limitations. First, it is retrospec-
tive, with all the inaccuracies in data collection that this
may imply. However, the submitted questionnaire was
strongly structured, with mandatory fields and pre-
defined possible replies, ensuring a high degree of stan-
dardization; moreover, the large number of patients and
procedures collected strengthen the conclusions. Second, a
comparative population of normal subjects undergoing the
same invasive procedures would have provided a better
quantification of the excess surgical bleeding risk. This
was indeed planned in the study protocol, but it was
impossible to collect enough control cases. However, for
the few surgical procedures in healthy controls collected,
frequency of post-surgical bleeding was strikingly lower (1
of 34; 3%), and similar to the estimated hemorrhagic com-
plications rate of surgery (1.4% to 6%) in otherwise
healthy subjects.30,36 Third, for specific disorders, such as
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CalDAG-related platelet disorder, combined α/δ granule
deficiency, and Scott syndrome, the exact bleeding risk
could not be estimated, because only a few procedures
were available, reflecting their rarity. However, our results
provide a first useful hint of the surgical bleeding pheno-
type of these forms. Fourth, we do not have information
about possible side effects of the pro-hemostatic proce-
dures employed, or about other concomitant factors that
may have increased the risk of surgical bleeding (e.g. blood
pressure, acquired coagulopathy, VWD, abnormalities of
whole cell count).
In conclusion, our study shows that surgery-related
bleeding risk is substantial in IPDs, especially in IPFDs,
that the bleeding history, some specific disorders and
female sex are predictors of the bleeding risk, and that
some types of invasive procedures are at particularly high
risk. Importantly, prophylactic treatment is associated
with a significant reduction of the bleeding frequency in
IPFDs. 
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